Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer
Clinical trial NCT04717531 · UNKNOWN
Trial details
- NCT number
- NCT04717531
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-06-03
- Primary completion
- 2023-06-01
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.